Permalink
Prev
Next
Return to results list
Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
Table Of Contents
Download PDF Previous Fragment Next Fragment
-
Senate Journal No. 131 - 6 February 2013
- 1 MEETING OF SENATE
- 2 GOVERNMENT DOCUMENTS
- 3 AMERICAN LEGISLATIVE EXCHANGE COUNCIL—PERSONAL EXPLANATION
- 4 WATER AMENDMENT (WATER FOR THE ENVIRONMENT SPECIAL ACCOUNT) E BILL 2012
- 5 MATTERS OF PUBLIC INTEREST
- 6 QUESTIONS
- 7 QUESTION ON NOTICE—ANSWER AND EXPLANATION
- 8 MOTIONS TO TAKE NOTE OF ANSWERS
- 9 NOTICES
- 10 RURAL AND REGIONAL AFFAIRS AND TRANSPORT REFERENCES COMMITTEE—EXTENSION OF TIME TO REPORT
- 11 NOTICES OF MOTION WITHDRAWN
- 12 QUESTION TIME—MODIFIED RULES—CONSIDERATION OF PRIVATE SENATORS' BILLS—ROUTINE OF BUSINESS—TEMPORARY ORDERS
- 13 AUSTRALIAN SPORTS ANTI-DOPING AUTHORITY AMENDMENT BILL 2013
- 14 ENVIRONMENT AND COMMUNICATIONS REFERENCES COMMITTEE—EXTENSION OF TIME TO REPORT
- 15 ECONOMICS LEGISLATION COMMITTEE—LEAVE TO MEET DURING SITTING
- 16 PUBLIC ACCOUNTS AND AUDIT—JOINT STATUTORY COMMITTEE—LEAVE TO MEET DURING SITTINGS
- 17 CORPORATIONS AND FINANCIAL SERVICES—JOINT STATUTORY COMMITTEE—LEAVE TO MEET DURING SITTINGS
- 18 AUSTRALIAN COMMISSION FOR LAW ENFORCEMENT INTEGRITY—JOINT STATUTORY COMMITTEE—LEAVE TO MEET DURING SITTINGS
- 19 LEGAL AND CONSTITUTIONAL AFFAIRS LEGISLATION COMMITTEE—LEAVE TO MEET DURING SITTING
- 20 CONSTITUTIONAL RECOGNITION OF ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLES—JOINT SELECT COMMITTEE—LEAVE TO MEET DURING SITTING
- 21 LAW ENFORCEMENT—JOINT STATUTORY COMMITTEE—LEAVE TO MEET DURING SITTINGS
- 22 COMMUNITY AFFAIRS LEGISLATION COMMITTEE—COMMUNITY AFFAIRS REFERENCES COMMITTEE—LEAVE TO MEET DURING SITTINGS
- 23 FINANCE AND PUBLIC ADMINISTRATION REFERENCES COMMITTEE—EXTENSION OF TIME TO REPORT
- 24 TAXATION—MINERALS RESOURCE RENT TAX—ADVICE—ORDER FOR PRODUCTION OF DOCUMENTS
- 25 TAXATION—COLLECTIVE INVESTMENT VEHICLES—ORDER FOR PRODUCTION OF DOCUMENTS
- 26 LAW AND JUSTICE—STOCK MARKET TRADING—MEDIA RELEASE HOAX
- 27 LAW AND JUSTICE—LEGAL SERVICES
- 28 TAXATION—MINERALS RESOURCE RENT TAX—REVENUE—ORDER FOR PRODUCTION OF DOCUMENTS
- 29 FINANCE—FINAL BUDGET OUTCOME
- 30 ENVIRONMENT—TASMANIAN WILDERNESS WORLD HERITAGE AREA
- 31 NOTICE
- 32 FAMILY AND COMMUNITY SERVICES—NEWSTART
- 33 FOREIGN AFFAIRS—AUTOMATIC TAX INFORMATION EXCHANGE
- 34 DISCUSSION OF MATTER OF PUBLIC IMPORTANCE—ENVIRONMENT—RENEWABLE ENERGY
- 35 SCRUTINY OF BILLS—STANDING COMMITTEE—1ST REPORT AND ALERT DIGEST NO. 1 OF 2013
- 36 HUMAN RIGHTS—JOINT STATUTORY COMMITTEE—1ST REPORT OF 2013
- 37 AUSTRALIAN PARLIAMENTARY DELEGATION TO THE UNITED KINGDOM AND POLAND—DOCUMENT
- 38 DOCUMENTS
- 39 DEPARTMENTAL AND AGENCY APPOINTMENTS AND VACANCIES—ORDER FOR PRODUCTION OF DOCUMENTS—DOCUMENTS
- 40 DEPARTMENTAL AND AGENCY GRANTS—ORDER FOR PRODUCTION OF DOCUMENTS—DOCUMENT
- 41 CRIMES LEGISLATION AMENDMENT (ORGANISED CRIME AND OTHER MEASURES) BILL 2012E SOCIAL SECURITY AND OTHER LEGISLATION AMENDMENT (INCOME SUPPORT BONUS) BILL 2012
- 42 CONSTITUTIONAL RECOGNITION OF LOCAL GOVERNMENT—JOINT SELECT COMMITTEE—VARIATION OF APPOINTMENT
- 43 COMMITTEE MEMBERSHIP
- 44 HUMAN RIGHTS—JOINT STATUTORY COMMITTEE—1ST REPORT OF 2013—CONSIDERATION
- 45 MIGRATION AMENDMENT REGULATION 2012—PROPOSED DISALLOWANCE
- 46 WATER AMENDMENT (WATER FOR THE ENVIRONMENT SPECIAL ACCOUNT) E BILL 2012
- 47 NOTICE
- 48 GOVERNMENT DOCUMENTS—CONSIDERATION
- 49 ADJOURNMENT
- 50 ATTENDANCE
Content Window
NOTICESenators Xenophon and Madigan gave a notice of motion as follows: To move on the next day of sitting—That the following matters be referred to the Community Affairs References Committee for inquiry and report by 21 March 2013: (a) the operation of the Pharmaceutical Benefits Scheme price disclosure mechanism; (b) the effect of past price disclosure decisions and subsequent price reductions on the supply of chemotherapy drugs such as Docetaxel, particularly in relation to: (i) patient access to treatment, (ii) cost to pharmacists and suppliers, and (iii) cost to the private and public hospital systems; (c) the effect of future price disclosure decisions and subsequent price reductions on the supply of chemotherapy drugs, particularly in relation to patient access to treatment; and (d) any related matters. | |